On October 10th, 2023, AstraZeneca announced that the Ministry of Science and Technology has issued a certificate of technology transfer registration for AstraZeneca to transfer the technology of production and packaging processes to Medochemie to produce innovative pharmaceutical products in Vietnam.
According to the terms of the technology transfer agreement, Medochemie will adhere to AstraZeneca’s high international quality standards in all related processes. AstraZeneca will provide appropriate support to Medochemie in terms of personnel, experts, technological chains, machinery and equipment, technical documents, and production, testing, and launch processes, to ensure that AstraZeneca’s technology transferred pharmaceutical products produced in Vietnam meet the same standards, quality, and efficacy as the origin drugs produced in Europe, meeting AstraZeneca’s strict global standards.
Sharing about this collaboration, Mr. Nitin Kapoor, Chairman and CEO of AstraZeneca Vietnam said, “For many years, AstraZeneca has always made the health of the people and the sustainability of Vietnam’s healthcare system one of its key priorities in Vietnam. This event is a clear testament to AstraZeneca’s commitment to closely cooperate and enhance healthcare capacity, develop the domestic pharmaceutical industry, thereby aiming to provide patients with easy access to high-quality drugs produced in the country.”
Representatives of the two companies also expressed optimism as the project has been facilitated by the Ministry of Health and the Ministry of Science and Technology, reflecting the Vietnamese Government’s strategic vision for the development of the pharmaceutical industry, gradually creating an ecosystem to help patients access effective care and quality treatment.
Mr. Gregory Charitonos, Director of Medochemie Far East further shared, “Medochemie is delighted to be a partner of AstraZeneca in advancing Vietnam’s pharmaceutical industry. We view this collaboration as a pivotal step in our joint efforts and remain committed to working closely together to foster the development of Vietnam’s pharmaceutical and healthcare sectors.”
Earlier, during the announcement ceremony of a 2,000 billion Vietnamese dong (90 million USD) investment by AstraZeneca Group to support Vietnam in enhancing its domestic pharmaceutical production capacity, Prime Minister Pham Minh Chinh highly appreciated AstraZeneca’s expansion of long-term investment in Vietnam and affirmed that Vietnam will create the best conditions for AstraZeneca to invest and operate in the country. It is expected that in the period 2022-2030, three important AstraZeneca originator’s drugs will be transferred for production in Vietnam.
The National Strategy for the Development of Vietnam’s Pharmaceutical Industry until 2030 and the Program for the Development of Domestic Pharmaceutical Industry and Medicinal Materials until 2030, with a vision to 2045, have also identified promoting the development of the domestic pharmaceutical industry through innovative cooperation and international integration in pharmaceuticals, as well as constructing and implementing projects for the transfer of advanced and modern manufacturing technology for drugs.
Medochemie has invested in 5 high-tech pharmaceutical manufacturing plants in Vietnam. Medochemie’s manufacturing plants cover a total area of 63,500 square meters with 9 different production lines, with a special focus on high-quality technology transfer drugs produced for export to Europe and other countries worldwide, as well as supplying the domestic market.
Press release distributed by EloQ Communications.